Q-omics provides the consensus-scored RNY4P37 profile across patient tissues and cancer cell-line models. RNY4P37 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNY4P37 is differentially expressed in 7, with the highest sampling consensus in PAAD. Additionally, RNY4P37 RNA expression shows 12,396 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, PAAD, and UVM as cancer lineages where RNY4P37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNY4P37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNY4P37 survival associations across molecular data types. RNY4P37 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNY4P37 RNA expression–survival associations across cancer types. High RNY4P37 expression shows unfavorable associations in HNSC and THCA, but favorable associations in MESO, PAAD, UCS and STAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .025). Together, the overview and detailed table identify MESO as the clearest survival context for RNY4P37 RNA expression.
This table summarizes RNY4P37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNY4P37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNY4P37 shows lower tumor expression in PAAD, THCA, COAD, LUSC, KIRP and KIRC. The PAAD box plot shows higher RNY4P37 RNA expression in normal versus tumor tissue (log2 FC = −0.794, t-test p = .035).
This table shows molecular features associated with RNY4P37 in patient tissues and cancer cell lines. In patient samples, RNY4P37 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
